Literature DB >> 30137652

State-of-the-Art Review of HIV-TB Coinfection in Special Populations.

Ethel D Weld1, Kelly E Dooley1.   

Abstract

Children and pregnant and postpartum women experience an undue burden of HIV-associated tuberculosis (TB), but data are lacking on key aspects of their complex management. Often excluded from clinical trials, they are left with limited options for HIV-TB cotreatment. This review will focus on pharmacologic aspects of the treatment of HIV-TB coinfection in the special populations of children and pregnant and postpartum women. Pharmacogenomic considerations, rational dosing, drug-drug interactions, safety, immune reconstitution inflammatory syndrome, and ethical and policy aspects of the inclusion of special populations in research will be surveyed. Considerations related to the treatment of both HIV-associated TB disease and HIV-associated latent TB infection will be summarized. Relevant knowledge gaps and research priorities in special populations will be outlined.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30137652     DOI: 10.1002/cpt.1221

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.

Authors:  Clement Agoni; Pritika Ramharack; Elliasu Y Salifu; Mahmoud E S Soliman
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

2.  Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.

Authors:  Amita Gupta; Michael D Hughes; Anthony J Garcia-Prats; Katherine McIntire; Anneke C Hesseling
Journal:  PLoS Med       Date:  2019-08-15       Impact factor: 11.069

Review 3.  Advances in clinical trial design: Weaving tomorrow's TB treatments.

Authors:  Christian Lienhardt; Andrew Nunn; Richard Chaisson; Andrew A Vernon; Matteo Zignol; Payam Nahid; Eric Delaporte; Tereza Kasaeva
Journal:  PLoS Med       Date:  2020-02-27       Impact factor: 11.069

4.  New opportunities in tuberculosis prevention: implications for people living with HIV.

Authors:  Lucia González Fernández; Esther C Casas; Satvinder Singh; Gavin J Churchyard; Grania Brigden; Eduardo Gotuzzo; Wim Vandevelde; Suvanand Sahu; Sevim Ahmedov; Adeeba Kamarulzaman; Alfredo Ponce-de-León; Beatriz Grinsztejn; Susan Swindells
Journal:  J Int AIDS Soc       Date:  2020-01       Impact factor: 5.396

5.  "Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis.

Authors:  Marian Loveday; Sindisiwe Hlangu; Jennifer Furin
Journal:  PLoS One       Date:  2020-12-21       Impact factor: 3.240

6.  No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.

Authors:  Glauco Henrique Balthazar Nardotto; Valdes Roberto Bollela; Adriana Rocha; Oscar Della Pasqua; Vera Lucia Lanchote
Journal:  Clin Transl Sci       Date:  2021-10-20       Impact factor: 4.689

7.  Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Authors:  Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.